Digital health companies' plans focused on managing the impact of GLP-1 drugs, which have placed enormous pressure on health ...

But, no matter what direction the general market takes, some stocks could stand out, potentially in 2025, and most ...

Popular obesity stocks fell on Tuesday after pharma giant Eli Lilly LLY lowered its sales guidance for full-year 2024 and announced disappointing preliminary fourth-quarter sales numbers. LLY’s ...